476 related articles for article (PubMed ID: 27555459)
21. Activated phosphoinositide 3-dinase delta syndrome (APDS): An update.
Lougaris V; Cancrini C; Rivalta B; Castagnoli R; Giardino G; Volpi S; Leonardi L; La Torre F; Federici S; Corrente S; Cinicola BL; Soresina A; Marseglia GL; Cardinale F
Pediatr Allergy Immunol; 2022 Jan; 33 Suppl 27(Suppl 27):69-72. PubMed ID: 35080319
[TBL] [Abstract][Full Text] [Related]
22. Early diagnosis of PI3Kδ syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
Saettini F; Pelagatti MA; Sala D; Moratto D; Giliani S; Badolato R; Biondi A
Immunol Lett; 2017 Oct; 190():279-281. PubMed ID: 28842185
[TBL] [Abstract][Full Text] [Related]
23. Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes.
Redenbaugh V; Coulter T
Front Pediatr; 2021; 9():702872. PubMed ID: 34422726
[TBL] [Abstract][Full Text] [Related]
24. Immunodeficiency due to a novel variant in PIK3CD: a case report.
Shashaani N; Chavoshzadeh Z; Ghasemi L; Ghotbabadi SH; Shiari S; Sharafian S; Shiari R
Pediatr Rheumatol Online J; 2023 Jul; 21(1):71. PubMed ID: 37475052
[TBL] [Abstract][Full Text] [Related]
25. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage.
Angulo I; Vadas O; Garçon F; Banham-Hall E; Plagnol V; Leahy TR; Baxendale H; Coulter T; Curtis J; Wu C; Blake-Palmer K; Perisic O; Smyth D; Maes M; Fiddler C; Juss J; Cilliers D; Markelj G; Chandra A; Farmer G; Kielkowska A; Clark J; Kracker S; Debré M; Picard C; Pellier I; Jabado N; Morris JA; Barcenas-Morales G; Fischer A; Stephens L; Hawkins P; Barrett JC; Abinun M; Clatworthy M; Durandy A; Doffinger R; Chilvers ER; Cant AJ; Kumararatne D; Okkenhaug K; Williams RL; Condliffe A; Nejentsev S
Science; 2013 Nov; 342(6160):866-71. PubMed ID: 24136356
[TBL] [Abstract][Full Text] [Related]
26. Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome.
Wang Y; Wang W; Liu L; Hou J; Ying W; Hui X; Zhou Q; Liu D; Yao H; Sun J; Wang X
J Clin Immunol; 2018 Nov; 38(8):854-863. PubMed ID: 30499059
[TBL] [Abstract][Full Text] [Related]
27. Activated Phosphoinositide 3-Kinase δ Syndrome: a Large Pediatric Cohort from a Single Center in China.
Qiu L; Wang Y; Tang W; Yang Q; Zeng T; Chen J; Chen X; Zhang L; Zhou L; Zhang Z; An Y; Tang X; Zhao X
J Clin Immunol; 2022 May; 42(4):837-850. PubMed ID: 35296988
[TBL] [Abstract][Full Text] [Related]
28. Systematic review of mortality and survival rates for APDS.
Hanson J; Bonnen PE
Clin Exp Med; 2024 Jan; 24(1):17. PubMed ID: 38280023
[TBL] [Abstract][Full Text] [Related]
29. Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.
Maccari ME; Abolhassani H; Aghamohammadi A; Aiuti A; Aleinikova O; Bangs C; Baris S; Barzaghi F; Baxendale H; Buckland M; Burns SO; Cancrini C; Cant A; Cathébras P; Cavazzana M; Chandra A; Conti F; Coulter T; Devlin LA; Edgar JDM; Faust S; Fischer A; Garcia-Prat M; Hammarström L; Heeg M; Jolles S; Karakoc-Aydiner E; Kindle G; Kiykim A; Kumararatne D; Grimbacher B; Longhurst H; Mahlaoui N; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neven B; Nieters A; Olbrich P; Ozen A; Pachlopnik Schmid J; Picard C; Prader S; Rae W; Reichenbach J; Rusch S; Savic S; Scarselli A; Scheible R; Sediva A; Sharapova SO; Shcherbina A; Slatter M; Soler-Palacin P; Stanislas A; Suarez F; Tucci F; Uhlmann A; van Montfrans J; Warnatz K; Williams AP; Wood P; Kracker S; Condliffe AM; Ehl S
Front Immunol; 2018; 9():543. PubMed ID: 29599784
[TBL] [Abstract][Full Text] [Related]
30. A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report.
Li GM; Liu HM; Guan WZ; Xu H; Wu BB; Feng JY; Sun L
Medicine (Baltimore); 2019 May; 98(18):e15329. PubMed ID: 31045771
[TBL] [Abstract][Full Text] [Related]
31. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome-like immunodeficiency.
Tsujita Y; Mitsui-Sekinaka K; Imai K; Yeh TW; Mitsuiki N; Asano T; Ohnishi H; Kato Z; Sekinaka Y; Zaha K; Kato T; Okano T; Takashima T; Kobayashi K; Kimura M; Kunitsu T; Maruo Y; Kanegane H; Takagi M; Yoshida K; Okuno Y; Muramatsu H; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Kojima S; Ogawa S; Ohara O; Okada S; Kobayashi M; Morio T; Nonoyama S
J Allergy Clin Immunol; 2016 Dec; 138(6):1672-1680.e10. PubMed ID: 27426521
[TBL] [Abstract][Full Text] [Related]
32. A Rare Case of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Presenting With Hemophagocytosis Complicated With Hodgkin Lymphoma.
Cansever M; Zietara N; Chiang SCC; Ozcan A; Yilmaz E; Karakukcu M; Rohlfs M; Somekh I; Canoz O; Abdulrezzak U; Bryceson Y; Klein C; Unal E; Patiroglu T
J Pediatr Hematol Oncol; 2020 Mar; 42(2):156-159. PubMed ID: 31033788
[TBL] [Abstract][Full Text] [Related]
33. Case Report: First Occurrence of Plasmablastic Lymphoma in Activated Phosphoinositide 3-Kinase δ Syndrome.
Yin Z; Tian X; Zou R; He X; Chen K; Zhu C
Front Immunol; 2021; 12():813261. PubMed ID: 34992612
[TBL] [Abstract][Full Text] [Related]
34. Activated Phosphoinositide 3-Kinase Delta Syndrome 1: Clinical and Immunological Data from an Italian Cohort of Patients.
Tessarin G; Rossi S; Baronio M; Gazzurelli L; Colpani M; Benvenuto A; Zunica F; Cardinale F; Martire B; Brescia L; Costagliola G; Luti L; Casazza G; Menconi MC; Saettini F; Palumbo L; Girelli MF; Badolato R; Lanzi G; Chiarini M; Moratto D; Meini A; Giliani S; Bondioni MP; Plebani A; Lougaris V
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33080915
[TBL] [Abstract][Full Text] [Related]
35. Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase δ Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.
Karanovic D; Michelow IC; Hayward AR; DeRavin SS; Delmonte OM; Grigg ME; Dobbs AK; Niemela JE; Stoddard J; Alhinai Z; Rybak N; Hernandez N; Pittaluga S; Rosenzweig SD; Uzel G; Notarangelo LD
Front Immunol; 2019; 10():77. PubMed ID: 30891027
[TBL] [Abstract][Full Text] [Related]
36. [Activated phosphoinositide 3-kinase δ syndrome presenting with gut-associated T-cell lymphoproliferative disease].
Teranishi H; Ishimura M; Koga Y; Eguchi K; Sonoda M; Kobayashi T; Shiraishi S; Nakashima K; Ikegami K; Aman M; Yamamoto H; Takada H; Ohga S
Rinsho Ketsueki; 2017; 58(1):20-25. PubMed ID: 28190860
[TBL] [Abstract][Full Text] [Related]
37. Activated phosphoinositide 3-kinase δ syndrome caused by PIK3CD mutations: expanding the phenotype.
Zhao P; Huang J; Fu H; Xu J; Li T; Zhang X; Meng Q; Zhang L; Tan L; Zhang W; Chen H; Lu X; Ding Y; He X
Pediatr Rheumatol Online J; 2024 Jan; 22(1):24. PubMed ID: 38287413
[TBL] [Abstract][Full Text] [Related]
38. PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
Yazdani R; Hamidi Z; Babaha F; Azizi G; Fekrvand S; Abolhassani H; Aghamohammadi A
Endocr Metab Immune Disord Drug Targets; 2019; 19(7):941-958. PubMed ID: 30799802
[TBL] [Abstract][Full Text] [Related]
39. Novel PIK3CD mutations affecting N-terminal residues of p110δ cause activated PI3Kδ syndrome (APDS) in humans.
Takeda AJ; Zhang Y; Dornan GL; Siempelkamp BD; Jenkins ML; Matthews HF; McElwee JJ; Bi W; Seeborg FO; Su HC; Burke JE; Lucas CL
J Allergy Clin Immunol; 2017 Oct; 140(4):1152-1156.e10. PubMed ID: 28414062
[No Abstract] [Full Text] [Related]
40. Infections in activated PI3K delta syndrome (APDS).
Brodsky NN; Lucas CL
Curr Opin Immunol; 2021 Oct; 72():146-157. PubMed ID: 34052541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
